Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Psoriatic Arthritis (PsA) Clear all

Completed Not applicable Interventional

Diet Interventions in Psoriatic Arthritis

NCT04180904

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Diet 1, Diet 2; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years

Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Jan 13, 2025 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 3 Interventional

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

NCT00235885

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: adalimumab; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older

Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Abbott Park, Illinois

Source: ClinicalTrials.gov public record

Updated Aug 28, 2007 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 4 Interventional

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

NCT03419650

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: ACTHar; Drug
Lead sponsor: IRIS Research and Development, LLC; Other
Eligibility: 18 Years and older

Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Plantation, Florida

Source: ClinicalTrials.gov public record

Updated Aug 30, 2021 · Synced May 21, 2026, 6:56 PM EDT

Recruiting Phase 3 Interventional

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06869551

View directory record Official record

Conditions: Juvenile Psoriatic Arthritis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 17 Years

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Lancaster, California • Chicago, Illinois • Indianapolis, Indiana + 4 more

Source: ClinicalTrials.gov public record

Updated Apr 13, 2026 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

NCT01307423

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Apremilast 20mg, Apremilast 30mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older

Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 30
States / cities: Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more

Source: ClinicalTrials.gov public record

Updated Jun 13, 2022 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 2 Interventional Results available

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

NCT02969525

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Placebo, Bimekizumab; Other · Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older

Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 13
States / cities: San Diego, California • Aventura, Florida • Hagerstown, Maryland + 10 more

Source: ClinicalTrials.gov public record

Updated Mar 19, 2023 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT03895203

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab, Adalimumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older

Enrollment: 852 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Phoenix, Arizona • San Diego, California • Tustin, California + 22 more

Source: ClinicalTrials.gov public record

Updated Jan 26, 2026 · Synced May 21, 2026, 6:56 PM EDT

Recruiting Phase 1 Interventional

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193

View directory record Official record

Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Santa Monica, California • South Miami, Florida • Durham, North Carolina + 1 more

Source: ClinicalTrials.gov public record

Updated Apr 30, 2026 · Synced May 21, 2026, 6:56 PM EDT

Recruiting Not applicable Interventional

Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy

NCT06586281

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Guselkumab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Not listed

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Diego, California

Source: ClinicalTrials.gov public record

Updated Apr 2, 2025 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT03896581

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older

Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 33
States / cities: Phoenix, Arizona • San Diego, California • Tustin, California + 30 more

Source: ClinicalTrials.gov public record

Updated Jan 27, 2026 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

NCT03104400

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older

Enrollment: 1,705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 114
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more

Source: ClinicalTrials.gov public record

Updated Sep 21, 2025 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

NCT04109976

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older

Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Boise, Idaho • Lexington, Kentucky • Baton Rouge, Louisiana + 17 more

Source: ClinicalTrials.gov public record

Updated Nov 29, 2023 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 3 Interventional

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

NCT06588296

View directory record Official record

Conditions: Psoriatic Arthritis, Obesity
Interventions: Ixekizumab, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 81
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 21, 2026, 6:56 PM EDT

Completed Not applicable Interventional

Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)

NCT05631223

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Telemedicine; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 89 Years

Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Salt Lake City, Utah

Source: ClinicalTrials.gov public record

Updated Feb 16, 2026 · Synced May 21, 2026, 6:56 PM EDT

Not yet recruiting Phase 4 Interventional

Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

NCT07111494

View directory record Official record

Conditions: Psoriatic Arthritis (PsA)
Interventions: GLP-1 agonists, Nutrition Counseling; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older

Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Source: ClinicalTrials.gov public record

Updated Aug 12, 2025 · Synced May 21, 2026, 6:56 PM EDT

Completed No phase listed Observational

DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA

NCT02413749

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 89 Years

Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Source: ClinicalTrials.gov public record

Updated Aug 17, 2017 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis

NCT01752634

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Secukinumab (AIN457), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 21
States / cities: Peoria, Arizona • Aventura, Florida • Palm Harbor, Florida + 17 more

Source: ClinicalTrials.gov public record

Updated May 12, 2020 · Synced May 21, 2026, 6:56 PM EDT

Active, not recruiting Phase 3 Interventional Results available

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

NCT04908189

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Deucravacitinib, Placebo, Apremilast; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older

Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 24
States / cities: Mountain Brook, Alabama • Sacramento, California • Whittier, California + 21 more

Source: ClinicalTrials.gov public record

Updated Jun 12, 2025 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 4 Interventional Results available

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

NCT03747939

View directory record Official record

Conditions: Arthritis, Psoriatic
Interventions: Apremilast (CC-10004), Apremilast (CC-10004) Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older

Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 54
States / cities: Mesa, Arizona • Covina, California • Encino, California + 48 more

Source: ClinicalTrials.gov public record

Updated Oct 21, 2024 · Synced May 21, 2026, 6:56 PM EDT

Completed No phase listed Observational Accepts healthy volunteers

DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA

NCT03011242

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older

Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Source: ClinicalTrials.gov public record

Updated Aug 12, 2021 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

NCT01392326

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Secukinumab (75 mg), Secukinumab (150 mg), Placebo Comparator; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 20 more

Source: ClinicalTrials.gov public record

Updated Feb 3, 2016 · Synced May 21, 2026, 6:56 PM EDT

Recruiting Phase 4 Interventional

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

NCT06864026

View directory record Official record

Conditions: Psoriatic Arthritis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 53
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more

Source: ClinicalTrials.gov public record

Updated Feb 9, 2026 · Synced May 21, 2026, 6:56 PM EDT

Recruiting Phase 3 Interventional

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

NCT06671496

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older

Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 18 more

Source: ClinicalTrials.gov public record

Updated Apr 5, 2026 · Synced May 21, 2026, 6:56 PM EDT

Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

NCT02798211

View directory record Official record

Conditions: Psoriatic Arthritis
Interventions: Secukinumab 300 mg, Secukinumab 150 mg, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 57
States / cities: Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more

Source: ClinicalTrials.gov public record

Updated Oct 6, 2021 · Synced May 21, 2026, 6:56 PM EDT